Skip to main content

Table 5 Factors associated with pathological Gleason score ≥ 8 in entire cohort and each risk group

From: Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy

  Entire cohort
  Univariate analyses  
  OR 95%CI p-value
PSAD >0.345 vs ≤0.345 ng/ml/cc 1.510 0.697–3.280 0.296
% positive cores >21.4 vs ≤21.4% 1.350 0.739–2.450 0.331
% dominant side >37.5 vs ≤37.5% 1.440 0.788–2.620 0.237
% cancer extent >55.6 vs ≤55.6% 1.460 0.789–2.710 0.228
NCCN risk high vs intermediate 5.650 2.950–10.80 <0.001
  Intermediate-risk
  Univariate analyses  
  OR 95%CI p-value
PSAD >0.190 vs ≤0.190 ng/ml/cc 1.860 0.668–5.160 0.236
% positive cores >21.4 vs ≤21.4% 0.733 0.244–2.200 0.580
% dominant side >36.4 vs ≤36.4% 0.696 0.243–1.990 0.500
% cancer extent >57.1 vs ≤57.1% 1.660 0.590–4.650 0.338
  High-risk
  Univariate analyses
  OR 95%CI p-value
PSAD >0.345 vs ≤0.345 ng/ml/cc 1.100 0.412-2.930 0.849
% positive cores >35.0 vs ≤35.0% 1.260 0.483–3.310 0.632
% dominant side >40.0 vs ≤40.0% 2.100 0.912–4.830 0.081
% cancer extent >55.6 vs ≤55.6% 1.020 0.437–2.390 0.959
  1. OR Odds ratio, 95%CI 95% confidence interval, % dominant side % positive cores from dominant side, % cancer extent maximum % of cancer extent in each positive core, Bold indicates statistically significant